Development of single-domain antibodies (nanobodies) from Llama (Vicugna pacos) and therapeutic C7C peptides against protein S of SARS-CoV-2
Basic information
Slovak title:
Vývoj jednodoménových protilátok (nanoprotilátok) z lamy (Vicugna pacos) a terapeutických C7C peptidov proti proteínu S SARS-CoV-2
Registration No.:
1/0381/23
Source:
Scientific grant agency (Ministry of education, science, research and sport of the Slovak Republic)
Implementation time:
2023 - 2026
Principal (UVMP):
Bhide Mangesh Ramesh, prof. MVSc., PhD. (2023: % | 2024: % | 2025: % | 2026: %)
Principal workplace:
Laboratory of Biomedical Microbiology and Immunology
Principal workplace:
Laboratory of Biomedical Microbiology and Immunology
Contributors:
Bhide Katarína, RNDr., PhD. (2023: % | 2024: % | 2025: % | 2026: %)
Jozefiaková Jana, MVDr., PhD. (2023: % | 2024: % | 2025: % | 2026: %)
Mochnáčová Evelína, MVDr., PhD. (2023: % | 2024: % | 2025: % | 2026: %)
Field of study:
200 - Veterinary Sciences
Financial indicators
NON-CAPITAL FUNDING in €
CAPITAL FUNDING in €
Allocated
Spent
Allocated
Spent
Allocated / Spent
Allocated / Spent
2023
0
0
0
0
0 / 0
0 / 0
2024
0
0
0
0
0 / 0
0 / 0
2025
0
0
0
0
0 / 0
0 / 0
2026
0
0
0
0
0 / 0
0 / 0
Spolu
0
0
0
0
0 / 0
0 / 0
Anotation
SARS-CoV-2 naďalej zostáva globálnou hrozbou, keďže vakcíny neposkytujú 100% ochranu. Nevyhnutná je aj potreba účinnej liečby proti COVID-19 a podanie protilátok je jednou z možností v závažných prípadoch. Spomedzi protilátok majú jednodoménové protilátky (nanoprotilátky, prítomné u Camelidae) významný antivirálny potenciál. Ďalšími perspektívnymi molekulami s terapeutickým potenciálom sú malé peptidy (7-12 aminokyselín). Nanoprotilátky a peptidy, ktoré sa viažu na receptor viažucu doménu (Receptor binding domain, RBD) vírusu, môžu tento vírus účinne neutralizovať. Malá veľkosť, stabilita a ľahká produkcia nanoprotilátok a peptidov z nich robí vhodnejších kandidátov na vývoj liečiv. V tomto projekte sa zameriavame na produkciu nanoprotilátok z lamy a 7-mérnych peptidov použitím technológie fágového displeja. Ďalej sa budeme snažiť potvrdiť ich neutralizačné vlastnosti a bezpečnosť. Veríme, že nanoprotilátky a peptidy budú mať v blízkej budúcnosti vysoký potenciál transformovať sa na terapeutiká.
SARS-CoV-2 remains a global threat because vaccines are not providing complete protection against new variants. Aa a result, there is a unmet need for effective COVID-19 treatments. Treatment with antibodies is an effective choice. Single-domain antibodies (nanobodies) derived from camelid animals (e.g. llamas) have a high potential for treating viral infections. Another promising molecules with therapeutic potential are small peptides (7-12 amino acids). Nanobodies and peptides that bind to the receptor binding domain (RBD) of the virus can effectively neutralize this virus. Further, small size, stability and easy production of nanobodies and peptides make them more suitable for drug development. In this project we aim to produceseveral nanobodies from llama and 7-mer peptides using phage display technology. We further aim to confirm their virus neutralization abilityand test their non-toxicity. We believe that nanoantibodies and peptides will have high potential to be transformed into therapeutics in the near future.
Publication outputs
1
ADC
MOCHNÁČOVÁ, Evelína - BHIDE, Katarína - KUCKOVÁ, Katarína - JOZEFIAKOVÁ, Jana - MAĽARIK, Tomáš - BHIDE, Mangesh Ramesh. Antimicrobial cyclic peptides effectively inhibit multiple forms of Borrelia and cross the blood-brain barrier model. In: Scientific Reports. 2025. ISSN 2045-2322, Vol. 15, no. 1 (2025), art. no. 6147, p. [1-16]
(2024: 3.900 - IF, 4.300 - IF 5y, 0.874 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)
(2024: 3.900 - IF, 4.300 - IF 5y, 0.874 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)